AR106717A1 - Composiciones para tratar atrofia muscular espinal, kits, métodos de tratamiento, usos - Google Patents
Composiciones para tratar atrofia muscular espinal, kits, métodos de tratamiento, usosInfo
- Publication number
- AR106717A1 AR106717A1 ARP160103436A ARP160103436A AR106717A1 AR 106717 A1 AR106717 A1 AR 106717A1 AR P160103436 A ARP160103436 A AR P160103436A AR P160103436 A ARP160103436 A AR P160103436A AR 106717 A1 AR106717 A1 AR 106717A1
- Authority
- AR
- Argentina
- Prior art keywords
- weight
- alkyl
- heterocycloalkyl
- cycloalkyl
- hydrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Reivindicación 1: Una composición farmacéutica que comprende un compuesto de fórmula (1), en donde R¹ es hidrógeno o alquilo C₁₋₇; R² es hidrógeno, ciano, alquilo C₁₋₇, haloalquilo C₁₋₇ o cicloalquilo C₃₋₈; R³ es hidrógeno, alquilo C₁₋₇, o cicloalquilo C₃₋₈; A es N-heterocicloalquilo o NR¹²R¹³, en donde N-heterocicloalquilo comprende 1 ó 2 átomos de anillo de nitrógeno y está opcionalmente sustituido con 1, 2, 3 ó 4 sustituyentes seleccionados de R¹⁴; R¹² es heterocicloalquilo que comprende 1 átomo de anillo de nitrógeno, en donde heterocicloalquilo está opcionalmente sustituido con 1, 2, 3 ó 4 sustituyentes seleccionados de R¹⁴; R¹³ es hidrógeno, alquilo C₁₋₇ o cicloalquilo C₃₋₈; R¹⁴ se selecciona independientemente de nitrógeno, alquilo C₁₋₇, amino, amino-alquilo C₁₋₇, cicloalquilo y heterocicloalquilo C₃₋₈ o dos R¹⁴ juntos forman alquileno C₁₋₇; con la salvedad de que si A es N-heterocicloalquilo que comprende solo 1 átomo de anillo de nitrógeno, entonces al menos un sustituyente R¹⁴ es amino o amino-alquilo C₁₋₇; o una sal farmacéuticamente aceptable de los mismos; en donde la composición es una solución acuosa oral o un polvo seco adecuado para la constitución de una solución acuosa oral. Reivindicación 21: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 20, en donde la composición comprende: del 1 al 10% en peso de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-(2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona o una sal farmacéuticamente aceptable del mismo; del 5 al 15% del peso de un sistema de tampón seleccionado entre citrato, malato, maleato o tartrato o alternativamente ácido tartárico solo; del 40 al 70% en peso de un diluyente seleccionado entre manitol o una mezcla de manitol e isomalt; del 1 al 4% en peso de ácido ascórbico; del 0,5 al 2% en peso de edetato de disodio; del 0.5 al 2% en peso de PEG6000; del 1 al 8% en peso de un conservante seleccionado entre ácido sórbico o benzoato de sodio; del 0 al 3% en peso de un edulcorante seleccionado entre sucralosa o sacarina de sodio; y del 0 al 20% en peso de un aromatizante seleccionado entre sabor fresa o sabor vainilla; y en donde la cantidad total de ingredientes no excede del 100% en peso. Reivindicación 46: Una combinación de un modulador del corte y empalme del gen SMN2 y un citoprotector, para su uso en el tratamiento, prevención, retraso en la progresión y/o mejora de enfermedades causadas por una mutación inactivante o eliminación en el gen SMN1 y/o asociada con la pérdida o defecto de la función génica de SMN1, y/o para la protección de células implicadas en la patofisiología de la enfermedad.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15194297 | 2015-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR106717A1 true AR106717A1 (es) | 2018-02-14 |
Family
ID=54542056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160103436A AR106717A1 (es) | 2015-11-12 | 2016-11-10 | Composiciones para tratar atrofia muscular espinal, kits, métodos de tratamiento, usos |
Country Status (14)
Country | Link |
---|---|
US (2) | US20180289712A1 (es) |
EP (2) | EP3373972B1 (es) |
JP (1) | JP6659841B2 (es) |
KR (1) | KR102162062B1 (es) |
CN (1) | CN108289959B (es) |
AR (1) | AR106717A1 (es) |
AU (1) | AU2016353961B2 (es) |
BR (1) | BR112018009281B1 (es) |
CA (1) | CA3002494C (es) |
EA (1) | EA036399B1 (es) |
HK (1) | HK1256089A1 (es) |
IL (1) | IL258497B (es) |
MX (1) | MX2018005890A (es) |
WO (1) | WO2017080967A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3143025B1 (en) | 2014-05-15 | 2019-10-09 | F. Hoffmann-La Roche AG | Compounds for treating spinal muscular atrophy |
US10882868B2 (en) | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
MX2018005890A (es) | 2015-11-12 | 2018-08-15 | Hoffmann La Roche | Composiciones para tratar atrofia muscular espinal. |
ES2879995T3 (es) | 2015-12-10 | 2021-11-23 | Ptc Therapeutics Inc | Métodos para el tratamiento de la enfermedad de Huntington |
CN108137579B (zh) | 2015-12-10 | 2022-01-07 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
WO2018073141A1 (en) * | 2016-10-18 | 2018-04-26 | F. Hoffmann-La Roche Ag | New composition for treating sma |
EA201992878A1 (ru) | 2017-06-05 | 2020-05-08 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения болезни хантингтона |
MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
BR112019027717A2 (pt) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | métodos para tratar a doença de huntington |
SG10202002990XA (en) | 2017-08-04 | 2020-05-28 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
EP3684766A1 (en) * | 2017-09-22 | 2020-07-29 | H. Hoffnabb-La Roche Ag | Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives |
CA3078137A1 (en) | 2017-10-03 | 2019-04-11 | F. Hoffmann-La Roche Ag | New treatment of sma |
CN112135815A (zh) | 2018-03-27 | 2020-12-25 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
EP3814360A1 (en) | 2018-06-27 | 2021-05-05 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
KR20210025625A (ko) * | 2018-06-27 | 2021-03-09 | 리보르나 바이오사이언시스, 아이엔씨. | 척수성 근위축증 예방제 또는 치료제 |
AU2019294478B2 (en) | 2018-06-27 | 2023-03-23 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
WO2020079203A1 (en) * | 2018-10-19 | 2020-04-23 | F. Hoffmann-La Roche Ag | New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making |
CN114007613A (zh) | 2019-02-05 | 2022-02-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
EP3920928A4 (en) | 2019-02-06 | 2022-09-28 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING |
CN113966219A (zh) | 2019-06-12 | 2022-01-21 | 豪夫迈·罗氏有限公司 | Sma的新治疗方法 |
WO2021030766A1 (en) * | 2019-08-15 | 2021-02-18 | Biogen Ma Inc. | Combination therapy for spinal muscular atrophy |
WO2023057404A1 (en) | 2021-10-06 | 2023-04-13 | F. Hoffmann-La Roche Ag | Novel combined administration |
WO2023202501A1 (zh) * | 2022-04-18 | 2023-10-26 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1383409A (en) | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
US6774134B2 (en) | 2000-12-20 | 2004-08-10 | Bristol-Myers Squibb Company | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents |
JP4970932B2 (ja) * | 2003-03-11 | 2012-07-11 | トロフォ | コレスト−4−エン−3−オンの誘導体の医薬としての使用、これらを含む医薬組成物、新規誘導体及びそれらの製造方法 |
KR20060127909A (ko) | 2003-12-24 | 2006-12-13 | 비오타 사이언티픽 매니지먼트 피티와이 엘티디 | 호흡기 다핵체 바이러스 감염 치료용 다환 물질 |
US20060153920A1 (en) | 2004-09-24 | 2006-07-13 | Ketan Amin | Lyophilized pharmaceutical compositions |
FR2914188B1 (fr) * | 2007-03-28 | 2012-06-22 | Trophos | Nouvelle composition a base d'oxime de cholest-4-en-3-one |
WO2009151546A2 (en) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
US8986935B2 (en) | 2008-08-13 | 2015-03-24 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
JP2011529722A (ja) | 2008-08-14 | 2011-12-15 | カーディアック ペースメイカーズ, インコーポレイテッド | 音響通信リンクの性能評価および適合 |
EP2359812A1 (en) | 2010-01-18 | 2011-08-24 | Cephalon France | Oral lyophilised compositions |
US8703763B2 (en) | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
US8871756B2 (en) | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
GB201119538D0 (en) | 2011-11-10 | 2011-12-21 | Viral Ltd | Pharmaceutical compounds |
MX352861B (es) | 2011-12-30 | 2017-12-13 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
PL2809322T3 (pl) * | 2012-01-26 | 2019-11-29 | Ptc Therapeutics Inc | Związki do leczenia zaniku mięśni pochodzenia rdzeniowego |
MX354074B (es) * | 2012-02-10 | 2018-02-12 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
AU2013289938A1 (en) | 2012-07-13 | 2015-01-29 | Indiana University Research & Technology Corporation | Compounds for treatment of spinal muscular atrophy |
JP2016518421A (ja) | 2013-05-14 | 2016-06-23 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 呼吸器合胞体ウイルス感染症の処置および予防のためのアザ−オキソ−インドール |
RU2673542C2 (ru) | 2013-06-25 | 2018-11-28 | Ф. Хоффманн-Ля Рош Аг | Соединения для лечения спинальной мышечной атрофии |
AR099134A1 (es) | 2014-01-24 | 2016-06-29 | Hoffmann La Roche | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina |
EP3143025B1 (en) * | 2014-05-15 | 2019-10-09 | F. Hoffmann-La Roche AG | Compounds for treating spinal muscular atrophy |
MX2018005890A (es) | 2015-11-12 | 2018-08-15 | Hoffmann La Roche | Composiciones para tratar atrofia muscular espinal. |
-
2016
- 2016-11-08 MX MX2018005890A patent/MX2018005890A/es unknown
- 2016-11-08 CN CN201680066250.2A patent/CN108289959B/zh active Active
- 2016-11-08 EP EP16794290.3A patent/EP3373972B1/en active Active
- 2016-11-08 EP EP24156739.5A patent/EP4360707A2/en active Pending
- 2016-11-08 AU AU2016353961A patent/AU2016353961B2/en active Active
- 2016-11-08 WO PCT/EP2016/076905 patent/WO2017080967A1/en active Application Filing
- 2016-11-08 JP JP2018524450A patent/JP6659841B2/ja active Active
- 2016-11-08 BR BR112018009281-9A patent/BR112018009281B1/pt active IP Right Grant
- 2016-11-08 CA CA3002494A patent/CA3002494C/en active Active
- 2016-11-08 KR KR1020187016504A patent/KR102162062B1/ko active Protection Beyond IP Right Term
- 2016-11-08 EA EA201891103A patent/EA036399B1/ru not_active IP Right Cessation
- 2016-11-10 AR ARP160103436A patent/AR106717A1/es unknown
-
2018
- 2018-04-04 IL IL258497A patent/IL258497B/en unknown
- 2018-04-17 US US15/955,337 patent/US20180289712A1/en not_active Abandoned
- 2018-11-27 HK HK18115151.3A patent/HK1256089A1/zh unknown
-
2019
- 2019-11-15 US US16/685,431 patent/US11938136B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2017080967A1 (en) | 2017-05-18 |
BR112018009281A2 (pt) | 2018-11-06 |
EP3373972B1 (en) | 2024-03-20 |
EP3373972A1 (en) | 2018-09-19 |
AU2016353961B2 (en) | 2019-08-29 |
EA036399B1 (ru) | 2020-11-06 |
KR102162062B1 (ko) | 2020-10-07 |
BR112018009281B1 (pt) | 2023-10-31 |
US20180289712A1 (en) | 2018-10-11 |
MX2018005890A (es) | 2018-08-15 |
HK1256089A1 (zh) | 2019-09-13 |
JP6659841B2 (ja) | 2020-03-04 |
IL258497B (en) | 2021-07-29 |
US20200323856A1 (en) | 2020-10-15 |
CA3002494C (en) | 2021-01-12 |
EA201891103A1 (ru) | 2018-11-30 |
EP3373972C0 (en) | 2024-03-20 |
AU2016353961A1 (en) | 2018-04-26 |
BR112018009281A8 (pt) | 2019-02-26 |
EP4360707A2 (en) | 2024-05-01 |
CN108289959A (zh) | 2018-07-17 |
JP2018533605A (ja) | 2018-11-15 |
KR20180080317A (ko) | 2018-07-11 |
US11938136B2 (en) | 2024-03-26 |
IL258497A (en) | 2018-06-28 |
CN108289959B (zh) | 2021-07-16 |
CA3002494A1 (en) | 2017-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR106717A1 (es) | Composiciones para tratar atrofia muscular espinal, kits, métodos de tratamiento, usos | |
ES2657687T3 (es) | Derivados de pirrolopirimidina para uso en el tratamiento de infecciones virales | |
AU2018259831A1 (en) | 2-amino-quinoline derivatives | |
ES2793239T3 (es) | Inhibidores del bromodominio | |
ES2707885T3 (es) | Alquilpirimidinderivados para el tratamiento de infecciones víricas y otras enfermedades | |
ES2341572T3 (es) | Pirido(2,3-d)-pirimidinas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas. | |
ES2212580T3 (es) | Inhibidores de la proteina farnesil-transferasa para el tratamiento de artropatias. | |
CY1119813T1 (el) | Αλατα 2-φθορο-ν-μεθυλ-4-[7-(κινολιν-6-υλ-μεθυλ)-ιμιδαζο[1,2-β][1,2,4]τριαζιν-2-υλ]βενζαμιδιου και διαδικασιες που σχετιζονται με την παρασκευη αυτων | |
AR093532A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
CA2422377A1 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
EA201650029A1 (ru) | Пиразолопиридины и пиразолопиримидины | |
JP2012520861A5 (es) | ||
CY1109619T1 (el) | ΕΝΩΣΕΙΣ ΠΥΡΑΖΟΛΟ [3,4-b] ΠΥΡΙΔΙΝΗΣ ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΩΣ ΑΝΑΣΤΟΛΕΩΝ ΦΩΣΦΟΔΙΕΣΤΕΡΑΣΗΣ | |
RU2011142182A (ru) | Соединения | |
EA200501326A1 (ru) | Пиримидины и триазины, ингибирующие репликацию вич | |
UY39032A (es) | Compuestos heterocíclicos como agentes antivirales | |
ECSP13012654A (es) | Composiciones farmacéuticas | |
AR045913A1 (es) | Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina | |
AR032134A1 (es) | Compuestos derivados de propilo tienoisoxazolil- y tienilpirrazolil-fenoxi-substituidos utiles como antagonistas d4, composiciones farmaceuticas, procedimientos de preparacion, compuestos intermediarios y usos en la fabricacion de medicamentos | |
AR096728A1 (es) | Derivados de estratrieno-tiazol terapéuticamente activos | |
KR20230134135A (ko) | 폐 질환들의 치료를 위한 폐포 2 형 세포 (alveolartype 2 cell) 증식의 소분자 조절제들 | |
US11395816B2 (en) | Corroles for treating human cytomegalovirus infections | |
UA110245C2 (en) | 7-(heleroaryl-amino)-6,7,8,9-letrahydropyrido[1,2-a]indol acetic acid derivatives and their application as prostaglandin d2 receptor modulators | |
JPH06506192A (ja) | 阻害剤 | |
SI2864328T1 (en) | Pharmaceutically active compounds |